Theratechnologies (THERF) Upgraded to Buy at ValuEngine

Theratechnologies (OTCMKTS:THERF) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.

Separately, Royal Bank of Canada initiated coverage on shares of Theratechnologies in a report on Tuesday, September 4th. They issued a “sector perform” rating on the stock.

OTCMKTS:THERF traded down $0.04 during midday trading on Thursday, hitting $6.47. The company’s stock had a trading volume of 21,640 shares, compared to its average volume of 70,558. Theratechnologies has a fifty-two week low of $3.90 and a fifty-two week high of $11.25. The company has a current ratio of 2.89, a quick ratio of 2.52 and a debt-to-equity ratio of 1.38.

Theratechnologies (OTCMKTS:THERF) last issued its quarterly earnings results on Thursday, October 4th. The company reported $0.02 earnings per share for the quarter. Theratechnologies had a negative net margin of 17.11% and a negative return on equity of 17.75%. The company had revenue of $13.53 million for the quarter.

About Theratechnologies

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.

Recommended Story: Asset Allocation and Your Retirement

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply